Your SlideShare is downloading. ×
Oncology Quiz with answers
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Oncology Quiz with answers

483

Published on

Published in: Education, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
483
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
35
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. IASO Quiz 2013 Instituted by Dr Panda and Dr K Gopinath
  • 2. Identify this cancer survivor
  • 3. Identify this cancer survivor Lance Armstrong
  • 4. Following the 2012 USPSTF recommendation against PSA screening in all men, which group saw a decrease in screening frequency by PCPs? A. Men between 40-49yrs B. Men above 79 yrs C. Patients with previous highest PSA <2.49ng/ml D. All the above
  • 5. Following the 2012 USPSTF recommendation against PSA screening in all men, which group saw a decrease in screening frequency by PCPs? A. Men between 40-49yrs B. Men above 79 yrs C. Patients with previous highest PSA <2.49ng/ml D. All the above Cohn JA, et al. Urol Oncol. 2013 Aug 1. [Epub ahead of print]
  • 6. PSA screening is likely to reduce mortality due to prostate cancer. However the conclusion is likely to be affected by A. B. C. D. Selection Bias Lead and length Bias Exposure and measurement issues All the above
  • 7. PSA screening is likely to reduce mortality due to prostate cancer. However the conclusion is likely to be affected by A. B. C. D. Selection Bias Lead and length Bias Exposure and measurement issues All the above
  • 8. Urethral Cancer which invades bladder neck, single inguinal node 3cm is staged A. B. C. D. T4N2M0 T4N1M0 T2N1M0 T3N2M0
  • 9. Urethral Cancer which invades bladder neck, single inguinal node 3cm is staged A. B. C. D. T4N2M0 T4N1M0 T2N1M0 T3N2M0
  • 10. Micromets play an important role in the natural progression of urothelial cancer. What percentage of organ confined node negative bladder cancers recur following cystectomy? A. B. C. D. 25% 5% 40% 60%
  • 11. Micromets play an important role in the natural progression of urothelial cancer. What percentage of organ confined node negative bladder cancers recur following cystectomy? A. B. C. D. 25% 5% 40% 60% Bladder cancer: Diagnosis Therapeutics and Management. Ed.Cheryl T Lee and David P Wood. 2010 page 89.
  • 12. BCG for superficial bladder cancer can be potentiated for additional benefit if combined with which of the following: A. B. C. D. Mitomycin C Interferon Epirubicin None of the above
  • 13. BCG for superficial bladder cancer can be potentiated for additional benefit if combined with which of the following: A. B. C. D. Mitomycin C Interferon Epirubicin None of the above Zhu S et al. BMC cancer 2013,Jul 5; 13: 322. Pooled results of a recent meta-analysis of 21 RCT and 9 comparative studiess showed a better recurrence free survival for BCG+Epirubicin at the cost of an increase in toxicity.
  • 14. Intravesical BCG for non muscle invasive bladder cancer for older patients A. B. C. D. Improves Overall Survival Improves Bladder cancer specific survival Improves Os but not BCSS Improves OS and BCSS
  • 15. Intravesical BCG for non muscle invasive bladder cancer for older patients A. B. C. D. Improves Overall Survival Improves Bladder cancer specific survival Improves Os but not BCSS Improves OS and BCSS Spencer BA, et al. J Oncol Pract. 2013;9(2):92-98.
  • 16. Name the medicinal Plant/tree/seeds Supposed to enhance memory
  • 17. Name the medicinal Plant/tree/seeds Supposed to enhance memory Ginko biloba
  • 18. The correct statement below is: A. HPV vaccination is highly effective against development of cervical dysplasia B. HPV vaccination is highly effective against development of anal and cervical dysplasia C. HPV vaccination is highly effective against development of cervical, anal and oral dysplasia
  • 19. The correct statement below is: A. HPV vaccination is highly effective against development of cervical dysplasia B. HPV vaccination is highly effective against development of anal and cervical dysplasia C. HPV vaccination is highly effective against development of cervical, anal and oral dysplasia Palefsky et al. NEJM 2011;365(17):1576
  • 20. Vit D receptor Bsm1 polymorphism may represent a risk factor for _______ women with ovarian cancer A. B. C. D. Asian North American European South American
  • 21. Vit D receptor Bsm1 polymorphism may represent a risk factor for _______ women with ovarian cancer A. B. C. D. Asian North American European South American VDR Bsm1 polymorphism is generally no associated with Ovarian cancer risk. However a subgroup analysis of the study by Qin X et al ( Int J Gyn Cancer 2013. 23(7): 1178-83) showed european population to be at risk.
  • 22. Which is not a paraneoplastic syndrome associated with Lung Cancer A. B. C. D. Horner’ syndrome Lambert-Eaton Syndrome Sweet’s Syndrome Dermatomyositis
  • 23. Which is not a paraneoplastic syndrome associated with Lung Cancer A. B. C. D. Horner’ syndrome Lambert-Eaton Syndrome Sweet’s Syndrome Dermatomyositis The syndrome was first described in 1964 by Dr. Robert D Sweet. It was also known as Gomm-Button disease in honour of the first two patients diagnosed. It is characterized by erythematous well defined cutaneous papules associates with fever and is associated with haematologic malignancies like leukaemia, Rheumatoid Arthritis, IBD, Behcets Syndrome.
  • 24. The dividing line to discriminate 2R and 4R from 2L and 4L when staging Lung Cancer is A. Midline of trachea B. Right Border of Trachea C. Left border of Trachea
  • 25. The dividing line to discriminate 2R and 4R from 2L and 4L when staging Lung Cancer is A. Midline of trachea B. Right Border of Trachea C. Left border of Trachea
  • 26. Nodal station not amenable to be assessed by standard cervical mediastinoscopy for staging lung cancer A. B. C. D. Station 3 Station 6 Station 7 Station 5
  • 27. Nodal station not amenable to be assessed by standard cervical mediastinoscopy for staging lung cancer A. B. C. D. Station 3 Station 6 Station 7 Station 5
  • 28. This 62 yr old pathologist who has undergone complete resection for a lung cancer is staged pT2 N0 M0. He asks you regarding adjuvant therapy with Geftinib. Your answer is-A. Yes it is beneficial in stage Ib, II and IIIa lung cancer B. Adjuvant Geftinib benefits only wild type EGFR C. Adjuvant Geftinib benefits only mutant EGFR D. No benefit of Adjuvant Geftinib
  • 29. This 62 yr old pathologist who has undergone complete resection for a lung cancer is staged pT2 N0 M0. He asks you regarding adjuvant therapy with Geftinib. Your answer is-A. Yes it is beneficial in stage Ib, II and IIIa lung cancer B. Adjuvant Geftinib benefits only wild type EGFR C. Adjuvant Geftinib benefits only mutant EGFR D. No benefit of Adjuvant Geftinib Gross GD et al. JCO 2013; 31(17) 3320-26. Trial was stopped mid way due to lack of benefit
  • 30. Not associated with pleural Mesothelioma A. B. C. D. SV 40 infection Erionite exposure Thorium Dioxide therapy HPV Infection
  • 31. Not associated with pleural Mesothelioma A. B. C. D. SV 40 infection Erionite exposure Thorium Dioxide therapy HPV Infection Lung Cancer : Prevention, Management and Emerging Therapies. David J Stewart Ed. 2010; page 437.
  • 32. OCP and HRT use are associated with increase in breast cancer and Lung cancer A. True B. False
  • 33. OCP and HRT use are associated with increase in breast cancer and Lung cancer A. True B. False ILCC pooled analysis of 6 case control studies ( 1961 cases and 2609 controls) found a reduced risk of lung ca in HRT (Adeno and Small Cell) and OCP (Squamous CA)users. There was no dose response relationship with years of OCP/HRT. Pesatori AC et al. Br J Cancer 2013; 109(7) 1954-64.
  • 34. Which of the following is an inhibitor of PDGFR A. B. C. D. Dasatinib Vandetanib Sorafenib Imatinib
  • 35. Which of the following is an inhibitor of PDGFR A. B. C. D. Dasatinib Vandetanib Sorafenib Imatinib - VEGFR-2 DS DNA break repair Bcl-2
  • 36. Name the book by this Ethiopia born physician which talks of liver transplantation A. My Journey B. Another life C. Cutting for Stone D.Emperor’s Malady
  • 37. Name the book by this Ethiopia born physician which talks of liver transplantation A. My Journey B. Another life C. Cutting for Stone D.Emperor’s Malady
  • 38. Does higher UV radiation exposure of pregnant women reduce incidence of some childhood cancers A. Yes B. No
  • 39. Does higher UV radiation exposure of pregnant women reduce incidence of some childhood cancers A. Yes • • B. No Lombardi C et al. cancer Epidemiology, Biomarkers and Prevention 2013;22(6): 1118-1128 Results: For cases with UVR exposure of 5,111 Watt-hours/m2 or above, we estimated a reduction in odds of developing acute lymphoblastic leukemia (OR: 0.89, 95% CI: 0.81–0.99), hepatoblastoma (OR: 0.69, 95% CI: 0.48–1.00), and non-Hodgkin's lymphoma (OR: 0.71, 95% CI: 0.50–1.02) adjusting for mother's age, mother's race, and child's year of birth. We also observed a small increase in odds for intracranial/intraspinal embryonal tumors (OR: 1.29, 95% CI: 1.01–1.65). Conclusions: Our findings suggest that UVR during pregnancy may decrease the odds of some childhood cancers. Future studies should explore additional factors that may be correlated with UVR exposure and possibly include biomarkers of immune function and vitamin D.
  • 40. Melanoma subtype which is characterized by bland fibroblastic appearance and often mimics a scarA. B. C. D. Desmoplastic Acral Letigenous Nodular Lentigo maligna
  • 41. Melanoma subtype which is characterized by bland fibroblastic appearance and often mimics a scarA. B. C. D. Desmoplastic Acral Letigenous Nodular Lentigo maligna DM are strongly and homogeneously positive for S-100 protein but are often negative or only focally positive for melanocyte differentiation antigens such as tyrosinase, gp100, Melan-A, and microphthalmia transcription factor. DM differs from conventional melanoma in its clinical course. It is associated with a higher tendency for local recurrence, but metastases to regional lymph nodes are less common. Wood BA. Pathology 2013; 45(5): 453-463
  • 42. Who is this medical inventor A. Dr Eric Blom. B. Dr Robert Esther C. Dr Douglas J. Schwartzentruber
  • 43. Who is this medical inventor A. Dr Eric Blom. Inventor of the Blom Singer Prosthesis for laryngectomee patients B. Dr Robert Esther C. Dr Douglas J. Schwartzentruber Melanoma Vaccine
  • 44. Pet scan is often advised for follow-up in patients treated for HNSCC. Which of the following is correct statement A. PET scan does not obviate the need for standard radiology B. Two negative PET scans at 6 month intervals obviates the need for additional radiology C. Single negative PET scan obviates the need for additional radiology
  • 45. Pet scan is often advised for follow-up in patients treated for HNSCC. Which of the following is correct statement A. PET scan does not obviate the need for standard radiology B. Two negative PET scans at 6 month intervals obviates the need for additional radiology C. Single negative PET scan obviates the need for additional radiology Mc Dermott et al. AJNR 2013; 34(8): 1631-36 The NPV of 2 negative PET scans at 6 month intervals was 98% compared to 91% for a single negative PET scan
  • 46. Most likely site of an asymptomatic recurrence of H&N cancer is A. B. C. D. Thoracic Abdominal Regional nodal Primary site
  • 47. Most likely site of an asymptomatic recurrence of H&N cancer is A. B. C. D. Thoracic Abdominal Regional nodal Primary site Dunsky KA et al. Laryngoscope 2013; 123(9): 2161-64
  • 48. H&N Liposarcomas are likely to be A. Commonly deep and have poor outcome B. DFS and OS poorer than conventional liposarcoms C. Low grade and early stage D. Deep seated but low grade and stage
  • 49. H&N Liposarcomas are likely to be A. Commonly deep and have poor outcome B. DFS and OS poorer than conventional liposarcoms C. Low grade and early stage D. Deep seated but low grade and stage Gerry D et al. Head and Neck 2013; Jun 01 Epub
  • 50. Stage IVa H&N Melanoma is A. B. C. D. T1 N2 M0 T3 N1 M0 T4b N0 M0 T3 N2 M0
  • 51. Stage IVa H&N Melanoma is A. B. C. D. T1 N2 M0 T3 N1 M0 T4b N0 M0 T3 N2 M0
  • 52. One of the following is not implicated in the development of carcinoma of the larynx. A. B. C. D. Tobacco Leather Dust Strong Inorganic Mists Asbestos Dust and Fibre .
  • 53. One of the following is not implicated in the development of carcinoma of the larynx. A. B. C. D. Tobacco Leather Dust Strong Inorganic Mists Asbestos Dust and Fibre Head and Neck CA. Current Perspectives and Challenges. Ed James A Radosevich. 2013: page 58. The other 3 have a strong association. Others with limited evidence are HPV 16,18, Sulfur Mustard, Rubber production, secondary tobacco smoke. Less than 1% are due to alcohol alone.
  • 54. The journey of this physician’s discovery and clinical application was captured in a Hollywood movie in 2008 starring Harry Connick A. Living Proof B. A Gift of Life C. Nude Rats D.The Lonely Road
  • 55. The journey of this physician’s discovery and clinical application was captured in a Hollywood movie in 2008 starring Harry Connick A. Living Proof B. A Gift of Life C. Nude Rats D.The Lonely Road
  • 56. Triple negative breast cancers typically demonstrate A. B. C. D. Chemotherapy sensitivity Chemotherapy insensitivity Sensitive to only cisplatin Chemotherapy sensitivity followed shorter durable response
  • 57. Triple negative breast cancers typically demonstrate A. B. C. D. Chemotherapy sensitivity Chemotherapy insensitivity Sensitive to only cisplatin Chemotherapy sensitivity followed shorter durable response
  • 58. The residual tumour excised at surgery following neoadjuvant therapy with Trastuzumab and Chemotherapy is likely to have -A. B. C. D. Retained Her2 expression Gained Her2 point mutations Lost Her2 expression Lost Her2 point mutations
  • 59. The residual tumour excised at surgery following neoadjuvant therapy with Trastuzumab and Chemotherapy is likely to have -A. B. C. D. • Retained Her2 expression Gained Her2 point mutations Lost Her2 expression Lost Her2 point mutations In a study of 167 HER2-positive breast cancer patients, participants who received neoadjuvant chemotherapy without anti-HER2 treatment were more likely to demonstrate HER2 loss within their residual disease (40% vs 14.7%, P=0.019). Additionally, HER2 loss demonstrated a trend towards higher risk of relapse (HR 2.41, P=0.063). The pCR is confirmed as a powerful predictor of long-term outcome. The rate of HER2 loss is higher in patients receiving neoadjuvant CT without anti-HER2 agents. HER2 status on residual disease after preoperative therapy can be helpful in selecting patients at different risk of relapse, to be included in prospective trial exploring further adjuvant therapy. Guarneri V, et al. Ann Oncol. 2013 Sep 7. [Epub ahead of print]
  • 60. Which of the following predicts the possibility of recurrence in node negative breast cancer A. B. C. D. Lymphovascular invasion Age of patient Perineural spread Adjuvant radiotherapy
  • 61. Which of the following predicts the possibility of recurrence in node negative breast cancer A. B. C. D. Lymphovascular invasion Age of patient Perineural spread Adjuvant radiotherapy In a study of 716 patients with node-negative breast cancer, 47 ultimately recurred during 47 months of median follow-up. Lymphovascular invasion (HR 4.6) and Nottingham grade 3 (HR 4.99) tumors were independent risk factors associated with an increased risk of recurrence. Adjuvant radiotherapy (HR 0.35) decreased tumor recurrence, while adjuvant chemotherapy had no effect. Lin PH. J Surg Oncol 2013; 108(6): 352
  • 62. Your 52 yr old patient treated for HR+ EBC and now on Exemestrane says she is in the pink of health with no musculoskeletal symptoms, vasomotor or vulvovaginal symptoms. Inference on her survival-A. She likely to have a decreased survival B. No inference can be drawn C. She has same survival as for her stage of cancer D. She is likely to have a better survival
  • 63. Your 52 yr old patient treated for HR+ EBC and now on Exemestrane says she is in the pink of health with no musculoskeletal symptoms, vasomotor or vulvovaginal symptoms. Inference on her survival-A. B. C. D. She likely to have a decreased survival No inference can be drawn She has same survival as for her stage of cancer She is likely to have a better survival Fontein DB et al. JCO 2013; 31(18): 2257-64 International Tamoxifen Exemestrane Multinational Trial
  • 64. The drugs recommended for breast cancer risk reduction in a 50yr old postmenopausal lady with family history of breast cancer and dense breasts are A. Raloxifene or Tamoxifen B. Raloxifene only C. Raloxifene, Tamoxifen and Exemestrane
  • 65. The drugs recommended for breast cancer risk reduction in a 50yr old postmenopausal lady with family history of breast cancer and dense breasts are A. Raloxifene or Tamoxifen B. Raloxifene only C. Raloxifene, Tamoxifen and Exemestrane Moyer VA, et al. Ann Intern Med. 2013 Sep 24. USPSTF recommendations
  • 66. Attachment of H Pylori to the gastric epithelium leads to activation of NF-Kb and increased A. IL-8 B. VEGF C. MMP-2 D. HGF
  • 67. Attachment of H Pylori to the gastric epithelium leads to activation of NF-Kb and increased A. IL-8 B. VEGF C. MMP-2 D. HGF
  • 68. Use of S-1 a novel drug based on 5FU with Cisplatin compared to the standard Cisplatin + 5FU for gastric cancer reveals A. Cis plat + S-1 is more effective B. Increased incidence of Stomatitis, Febrile neutropenia C. Lower incidence of hand foot syndrome D. Increased treatment related deaths
  • 69. Use of S-1 a novel drug based on 5FU with Cisplatin compared to the standard Cisplatin + 5FU for gastric cancer reveals A. Cis plat + S-1 is more effective B. Increased incidence of Stomatitis, Febrile neutropenia C. Lower incidence of hand foot syndrome D. Increased treatment related deaths Ajani JA et al. Eur J Cancer 2013; 49(17):3616-24. CS is noninferior to CF and has improved safety
  • 70. What is not true for follow up of Stage II and III Colon Cancer A. 80% recurrences occur in the first 2-2.5 yrs B. CT abdomen and chest recommended annually for 3 yrs C. If surveillance colonoscopy is fine at 1 yr colonoscopy is done every 2 yrs D. PET scan can be recommended as part of a trial only
  • 71. What is not true for follow up of Stage II and III Colon Cancer A. 80% recurrences occur in the first 2-2.5 yrs B. CT abdomen and chest recommended annually for 3 yrs C. If surveillance colonoscopy is fine at 1 yr colonoscopy is done every 2 yrs D. PET scan can be recommended as part of a trial only ASCO endorsed the guideline prepared by CCO ( JCO Nov 2012 )
  • 72. Incorrect about carcinoid tumours A. Causes depletion of tyrosine B. Some patients may have dermatological manifestations in sun exposed parts C. 10% secrete excessive levels of Serotonin D. May produce tricuspid stenosis
  • 73. Incorrect about carcinoid tumours A. Causes depletion of tyrosine. The aminoacid depleted is tryptophan B. Some patients may have dermatological manifestations in sun exposed parts C. 10% secrete excessive levels of Serotonin D. May produce tricuspid stenosis
  • 74. This computer scientist and professor at Carnagie Mellon University was an author of a best seller called A. Alice project B. Time management C. Achieving your childhood dreams D.The last lecture
  • 75. This computer scientist and professor at Carnagie Mellon University was an author of a best seller called A. Alice project B. Time management C. Achieving your childhood dreams D.The last lecture by Randy Pausch
  • 76. The 5 year survival of stage 1 pancreatic cancer is-A. B. C. D. Less than 30% 50% 65% 5%
  • 77. The 5 year survival of stage 1 pancreatic cancer is-A. B. C. D. Less than 30% 50% 65% 5%
  • 78. In patients with nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs), when preoperative grading assessment is not achieved, which clinical variable is an excellent predictor of post-treatment nodal positivity? A. B. C. D. Radiological tumour size BMI Age Gender
  • 79. In patients with nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs), when preoperative grading assessment is not achieved, which clinical variable is an excellent predictor of post-treatment nodal positivity? A. B. C. D. Radiological tumour size BMI Age Gender Partelli S, et al. JAMA Surg. 2013;148(10):932-939.
  • 80. In patients with hepatocellular carcinoma (HCC) receiving transarterial therapy (TACE/TAE), which is NOT a prognostic factor for risk of death? A. B. C. D. Albumin > 3.6 g/dl Bilirubin > 17umol/l Tumour Size > 7 cm AFP >400ng/dl
  • 81. In patients with hepatocellular carcinoma (HCC) receiving transarterial therapy (TACE/TAE), which is NOT a prognostic factor for risk of death? A. B. C. D. Albumin > 3.6 g/dl Bilirubin > 17umol/l Tumour Size > 7 cm AFP >400ng/dl This is the hepatoma arterial embolization prognostic score. Kadalayil L, et al. Ann Oncol. 2013;24(10):2565-2570.
  • 82. For adult survivors of childhood cancer, which organ system is the most at-risk for disease during adulthood after exposure to treatment with potential toxicity? A. B. C. D. Pulmonary Haematopoietic Hepatic Gastrointestinal .
  • 83. For adult survivors of childhood cancer, which organ system is the most at-risk for disease during adulthood after exposure to treatment with potential toxicity? A. B. C. D. Pulmonary Haematopoietic Hepatic Gastrointestinal Less than 15% develop haematopoietic, hepatic, skeletal dysfunction. Other organs at risk are cardiac, neurologic, neurocognitive and endocrine. Hudson MM, et al. JAMA. 2013;309(22):2371-2381.
  • 84. What percentage of adult survivors of childhood cancer develop an adult neoplasm (benign and or malignant) A. B. C. D. 16% 45% 3% 0.5%
  • 85. What percentage of adult survivors of childhood cancer develop an adult neoplasm (benign and or malignant) A. B. C. D. 16% 45% 3% 0.5% Hudson MM, et al. JAMA. 2013;309(22):2371-2381.
  • 86. This actor was diagnosed with ---- in the film A. Leukaemia B. Brain Tumour C. Lymphosarcoma of Intestine
  • 87. Risk of recurrence in GIST after surgery is high (55% or more)in all except: A. B. C. D. More than 10 cm size in any location 2-5cm with mitosis 5 per 50HPF Mucosal invasion Mitosis >1 per 5HPF
  • 88. Risk of recurrence in GIST after surgery is high (55% or more)in all except: A. B. C. D. More than 10 cm size in any location 2-5cm with mitosis 5 per 50HPF Mucosal invasion Mitosis >1 per 5HPF
  • 89. Most of the GIST are positive for CD117. Approximately 8% are CD117 negative but PDGFRA positive. These tumours areA. Clinically indolent, located in small intestine B. Clinically aggressive, located in stomach and C. Clinically indolent, located in stomach,
  • 90. Most of the GIST are positive for CD117. Approximately 8% are CD117 negative but PDGFRA positive. These tumours areA. Clinically indolent, located in small intestine B. Clinically aggressive, located in stomach and C. Clinically indolent, located in stomach Haematology Oncology Clinics: Rare Cancers. Dec 2012. These PDGFRA positive tumours commonly are of epithelioid morphology and the commonest mutation is on exon 18 (D842V) which makes them resistant to TKI
  • 91. The expected DFS following non operative management of clinical CR of Stage I-III rectal cancer treated by neoadjuvant CCRT is A. B. C. D. 50% 80% 60% 40%
  • 92. The expected DFS following non operative management of clinical CR of Stage I-III rectal cancer treated by neoadjuvant CCRT is A. B. C. D. 50% 80% 60% 40% Solanki AA et al. Onco Targets and therapy 2013; 2013(6): 1097-1110
  • 93. Who is this surgeon A.Frank H. Netter B.B Fisher C.CW Lilliehei
  • 94. Who is this surgeon A. Frank H. Netter was an American surgeon and celebrated medical illustrator. The first edition of his Atlas of Human Anatomy — his "personal Sistine Chapel" — was published in 1989 and he was made a Fellow of the New York Academy of Medicine B. B Fisher C. CW Lilliehei
  • 95. Statistics: the incorrect statement is A. Type 1 error is fixed apriori B. Increasing sample size has no effect on type 2 error C. Doubling sample size does not affect confidence interval D. Sample size and effect size are inversely related
  • 96. Statistics: the incorrect statement is A. Type 1 error is fixed apriori B. Increasing sample size has no effect on type 2 error C. Doubling sample size does not affect confidence interval D. Sample size and effect size are inversely related
  • 97. Which is not a subtypes of Chondroma A. B. C. D. Ectochondroma Enchondroma Perosteal chondroma Soft tissue Chondroma
  • 98. Which is not a subtypes of Chondroma A. B. C. D. Ectochondroma Enchondroma Perosteal chondroma Soft tissue Chondroma
  • 99. What minimum dose of radiation is needed to produce a statistically superior response to bone pain A. B. C. D. 10 Gy 8 Gy 15 Gy 4 Gy
  • 100. What minimum dose of radiation is needed to produce a statistically superior response to bone pain A. B. C. D. 10 Gy 8 Gy 15 Gy 4 Gy Dennis K. Radiother Oncol 2013; 106(1) 5-14 In this systematic analysis the authors found that the minimum dose of 8Gy was needed to reduce pain in bone mets.
  • 101. Most common Uterine Sarcoma A. B. C. D. Carcinosarcoma Endometrial stromal sarcoma Leiomyosarcoma Adenosarcoma
  • 102. Most common Uterine Sarcoma A. B. C. D. Carcinosarcoma Endometrial stromal sarcoma Leiomyosarcoma Adenosarcoma
  • 103. He hypothesised the angiogenesis theory for cancer which states that a tumor is able to create its own blood supply. Dozens of cancer drugs were developed based on his research. A. B. C. D. Dr J Michael Bishop Dr Harold E Varmus Dr Judah Folkman Dr Brian J Druker
  • 104. He hypothesised the angiogenesis theory for cancer which states that a tumor is able to create its own blood supply. Dozens of cancer drugs were developed based on his research. A. Dr J Michael Bishop B. Dr Harold E Varmus Nobel for Oncogene 1989 C. Dr Judah Folkman D. Dr Brian J Druker Along with Nicholas B. Lydon and Charles Sawyers, Lasker for CML

×